Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors
TTI-101(一种首创的口服STAT3抑制剂)治疗晚期实体瘤患者的I期临床试验
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-24-2920
Tsimberidou, Apostolia M; Vining, David J; Arora, Sukeshi P; de Achaval, Sofia; Larson, Jeffrey; Kauh, John; Cartwright, Carrie; Avritscher, Rony; Alibhai, Imran; Tweardy, David J; Kaseb, Ahmed O